Please login to the form below

Not currently logged in
Email:
Password:

Ocaliva

This page shows the latest Ocaliva news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).

Latest news

  • Intercept hit hard as FDA issues Ocaliva safety notice Intercept hit hard as FDA issues Ocaliva safety notice

    Intercept claimed an accelerated FDA approval for Ocaliva in May 2016 and followed that with an EMA green light in December. ... damage. Ocaliva is a first-in-class drug that works by stimulating the farnesoid X receptor, reducing the production of bile.

  • BMS claims a win in mid-stage NASH trial BMS claims a win in mid-stage NASH trial

    elafibranor and Intercept's Ocaliva (obeticholic acid), which is already on the market for another indication (primary biliary cholangitis).

  • Intercept gets EU nod for rare liver disease therapy Intercept gets EU nod for rare liver disease therapy

    Intercept gets EU nod for rare liver disease therapy. Ocaliva approved as a combination treatment for primary biliary cholangitis. ... Ocaliva can now help fill an important unmet need for these patients," he added.

  • Gilead chalks up trial success for new NASH drug Gilead chalks up trial success for new NASH drug

    Allergan has been building a pipeline of candidates through a series of bolt-on acquisitions including Akarna Therapeutics and Tobira Therapeutics, while Intercept's home-grown Ocaliva (obeticholic acid) - already approved

  • CHMP backs Intercept's rare liver disease drug CHMP backs Intercept's rare liver disease drug

    CHMP backs Intercept's rare liver disease drug. Ocaliva on track for EU approval as analysts predict blockbuster sales. ... GBI Research recently predicted that Ocaliva could become a blockbuster therapy by 2022.

More from news
Approximately 6 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics